NKGen Biotech CEO to present troculeucel data at China forum Sep 18, 2025 08:05AM
NKGen receives FDA expanded access authorization for neurodegenerative therapy Jul 21, 2025 08:01AM
NKGen Biotech gives first dose of troculeucel to Alzheimer's patient Jul 10, 2025 04:31PM
NKGen Biotech (NKGN) to delist to OTC, Reverse Stock Split will not be Implemented Mar 4, 2025 01:01PM
NKGen Biotech (NKGN) Announces Publication of Phase 1 Troculeucel Clinical Trial Results for the Treatment of Alzheimer’s Disease Feb 13, 2025 08:04AM


Feb 12, 2025 08:06AM NKGen Biotech (NKGN) Receives U.S. FDA Fast Track Designation for Troculeucel for the Treatment of Moderate Alzheimer’s Disease
Dec 2, 2024 04:08PM NKGen Biotech (NKGN) Selected as Stalking Horse Bidder for NKMax
Nov 26, 2024 04:19PM NKGen Biotech (NKGN) Receives Notifications From Nasdaq Related to Delayed Quarterly Report and Decision of the Nasdaq Hearings Panel
Sep 12, 2024 08:06AM NKGen Biotech (NKGN) Positive Phase 1 Clinical Data in Moderate Alzheimer’s Disease Advances Troculeucel into Phase 2 with First Patient Dosed in Phase 1/2a Trial
Aug 22, 2024 04:41PM NKGen Biotech (NKGN) Receives Notification From Nasdaq Related to Delayed Quarterly Report
Jul 30, 2024 08:05AM NKGen Biotech (NKGN) Presents New Positive SNK01 Biomarker Data at the 2024 Alzheimer’s Association International Conference
Jul 15, 2024 08:05AM NKGen Biotech (NKGN) Appoints Marco Gottardis to its Board
Jun 12, 2024 01:08PM NKGen Biotech (NKGN) Presents Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy for Solid Tumors